Personalised Neoantigen Peptide Immunotherapy in Glioblastoma: From Pre-screening to Clinical Translation
- Pre-screening in glioblastoma – Identifying patients with sufficient tumour material and actionable neoantigen profiles for a personalised, targeted peptide-based immunotherapy
- Mechanistic basis and planned immune readouts – A targeted peptide-based approach designed to prime neoantigen-specific T-cell responses, with immune monitoring assays being established to capture activation, breadth, and durability once treatment begins
- Pathways to scalability – Identifying key drivers such as prediction accuracy, manufacturing performance, and workflow coordination that will enable future scaling of personalised peptide-based programmes